BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18836376)

  • 21. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion.
    Gupta NC; Rogers JS; Graeber GM; Gregory JL; Waheed U; Mullet D; Atkins M
    Chest; 2002 Dec; 122(6):1918-24. PubMed ID: 12475827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].
    Buchmann I; Guhlmann CA; Elsner K; Gfrörer W; Schirrmeister H; Kotzerke J; Buck A; Reske SN
    Nuklearmedizin; 1999; 38(8):319-22. PubMed ID: 10615665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
    J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
    Pillot G; Siegel BA; Govindan R
    J Thorac Oncol; 2006 Feb; 1(2):152-9. PubMed ID: 17409845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
    Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
    Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer.
    Ryu JS; Ryu HJ; Lee SN; Memon A; Lee SK; Nam HS; Kim HJ; Lee KH; Cho JH; Hwang SS
    J Clin Oncol; 2014 Mar; 32(9):960-7. PubMed ID: 24550423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
    Borst GR; Belderbos JS; Boellaard R; Comans EF; De Jaeger K; Lammertsma AA; Lebesque JV
    Eur J Cancer; 2005 Jul; 41(11):1533-41. PubMed ID: 15953716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG PET of pleural effusions in patients with non-small cell lung cancer.
    Erasmus JJ; McAdams HP; Rossi SE; Goodman PC; Coleman RE; Patz EF
    AJR Am J Roentgenol; 2000 Jul; 175(1):245-9. PubMed ID: 10882281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer.
    Korkmaz T; Seber S; Okutur K; Basaran G; Yumuk F; Dane F; Ones T; Polat O; Madenci OC; Demir G; Turhal NS
    Biomarkers; 2013 Feb; 18(1):88-94. PubMed ID: 23116493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
    Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
    J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer.
    Tanvetyanon T; Eikman EA; Sommers E; Robinson L; Boulware D; Bepler G
    J Clin Oncol; 2008 Oct; 26(28):4610-6. PubMed ID: 18824709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
    Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
    Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
    Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.
    Downey RJ; Akhurst T; Gonen M; Park B; Rusch V
    J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1419-27. PubMed ID: 17532932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of Glut-1 glucose transporter expression with.
    Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
    Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
    Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
    J Nucl Med; 1999 Aug; 40(8):1241-5. PubMed ID: 10450672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.